https://www.medrxiv.org/content/10.1101/2021.10.10.21264827v1.full.pdf
Heterologous second doses were well-tolerated and effective. This trial didn't look at third dose boosters, but there is another trial looking at heterologous third dose boosters.
I think I'll be getting a Moderna booster with my Pfizer primary series pending approval. Pfoderna looks solid in this immunological data.
I should emphasize here this is just immunological data against pseudoviruses and not real world vaccine effectiveness data. In general antibody levels have a correlation with vaccine effectiveness, but it may be different. Likewise the durability of the immune response may be different. But this data indicates the heterologous doses are safe and generate good immune responses.
I should emphasize too here this is just immunological data against pseudoviruses and not real world vaccine effectiveness data. In general antibody levels have a correlation with vaccine effectiveness, but it may be different. We will have to see in that regard. Also in regards to durability of the immune response.
J&J is holding up against Delta and its immunity likewise isn't having much decline but its effectiveness is definitely lower than the mRNA vaccines, and the second dose really has a good benefit. They'll discuss J&J boosters on Friday as well. I'll be interested what they decide. It might be that they recommend all J&J recipients to get boosters. I think it is justified at this point.